Alnylam Pharma (ALNY) Tops Q3 EPS by 5c

Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($0.58), $0.05 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $11 million versus the consensus estimate of $8.93 million.

At September 30, 2014, Alnylam had cash, cash equivalents and total marketable securities of $915.2 million, as compared to $350.5 million at December 31, 2013.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance
• COPT Defense Properties (CDP) Reports In-Line Q1 EPS; offers guidance